XTLB — XTL BIOPHARMACEUTICALS LTD
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
As of Q2 2026, 3 SEC-registered investment managers reported holding XTLB (XTL BIOPHARMACEUTICALS LTD) in their latest 13F filings, with a combined reported value of $20.65K across 7.57K shares. That is -20.6% by share count (-1.93K shares) versus the previous quarter, while reported value moved -10.1%. Ownership is concentrated: the five largest holders account for 100.0% of reported value and the top ten for 100.0%.
Compared with the prior quarter, 1 opened new positions, 1 added to existing stakes, 1 trimmed, 4 exited entirely. 13F holdings are quarter-end snapshots, so these moves reflect positioning as of Q2 2026, not real-time trading.
Major shareholders of XTL BIOPHARMACEUTICALS LTD (XTLB) include Noked Israel Ltd, Renaissance Technologies, Citadel Advisors, ranked by reported 13F value among the 13 institutional holders on this page.
XTLB is classified in the Health Care sector.
All figures on this page are computed from SEC Form 13F quarterly filings. 13F filers disclose long positions of $100,000 or more within 45 days of quarter end; short positions, options overlays and intra-quarter trades are not included, so treat the numbers as a quarterly snapshot of institutional ownership rather than real-time positioning.
Institutional Ownership by Quarter
| Quarter | Funds holding | Shares | Value | QoQ Net Change |
|---|---|---|---|---|
| Q3 2026 | 3 | 10.73K | $25.37K | +41.9% |
| Q2 2026 | 3 | 7.57K | $20.65K | -20.6% |
| Q1 2026 | 6 | 72.70K | $175.38K | -75.7% |
| Q4 2025 | 6 | 329.73K | $190.88K | +2.0% |
| Q3 2025 | 4 | 226.92K | $265.80K | -0.7% |
| Q2 2025 | 4 | 228.50K | $261.10K | +1.8% |
| Q1 2025 | 4 | 248.30K | $298.68K | -2.2% |
| Q4 2024 | 3 | 228.19K | $462.74K | -1.6% |
Over the 8 quarters shown, institutional share counts decreased 95% in aggregate (Q4 2024 → Q3 2026); the largest single-quarter swing was Q1 2026 (-75.7%).
Top Institutional Holders (Q3 2026) — 3 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 6.87K | $16.49K | 0.00% | Add | |
| 3.44K | $7.90K | 0.00% | Add | |
| 427 | $983 | 0.00% | Add |
Holder history for earlier quarters, one table per quarter: Back to the Top 25 holders
Q2 2026 — 3 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 6.23K | $17.00K | 0.00% | Add | |
| 1.21K | $3.31K | 0.00% | Reduce | |
| 125 | $341 | 0.00% | New |
Q1 2026 — 6 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 49.72K | $120.00K | 0.02% | Reduce | |
| 13.35K | $32.18K | 0.01% | New | |
| 5.99K | $14.43K | 0.00% | Reduce | |
| 3.39K | $8.16K | 0.00% | Reduce | |
| 244 | $588 | 0.00% | New | |
| 10 | $24 | 0.00% | Reduce |
Q4 2025 — 6 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 198.89K | $115.00K | 0.02% | Hold | |
| 75.87K | $44.00K | 0.00% | New | |
| 30.11K | $17.46K | 0.00% | Add | |
| 12.89K | $7.47K | 0.00% | New | |
| 10.24K | $5.94K | 0.00% | New | |
| 1.74K | $1.01K | 0.00% | Reduce |
Q3 2025 — 4 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 198.89K | $233.00K | 0.04% | Hold | |
| 17.26K | $20.19K | 0.00% | Hold | |
| 10.01K | $11.71K | 0.00% | Reduce | |
| 763 | $893 | 0.00% | Reduce |
Q2 2025 — 4 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 198.89K | $227.00K | 0.04% | Hold | |
| 17.26K | $20.02K | 0.00% | Add | |
| 11.01K | $12.55K | 0.00% | Reduce | |
| 1.34K | $1.52K | 0.00% | New |
New Positions (Q2 2026)
- UBS Group AG 125 sh · $341
Fully Exited (vs previous quarter)
- Noked Israel Ltd sold 49.72K sh · $120.00K
- SmartHarvest Portfolios, LLC sold 13.35K sh · $32.18K
- Tower Research Capital LLC (TRC) sold 244 sh · $588
- Morgan Stanley sold 10 sh · $24
Fund Position History — shares by quarter (top 13 funds)
| Fund | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RHUMBLINE ADVISERS | 6.87K | 6.23K | 5.99K | 30.11K | 17.26K | 17.26K | 10.95K | 10.95K | 6.52K | 5.58K | — | — | — | — | — | — | — | — | — | — |
| GAMMA Investing LLC | 3.44K | 1.21K | 3.39K | 12.89K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| UBS Group AG | 427 | 125 | — | — | 763 | 1.34K | — | — | — | — | 6.95K | 54 | 120 | — | — | 300 | — | — | 812 | 154 |
| Noked Israel Ltd | — | — | 49.72K | 198.89K | 198.89K | 198.89K | 198.89K | 198.89K | 198.89K | 198.89K | 198.89K | 198.89K | 198.89K | — | — | — | — | — | — | — |
| Morgan Stanley | — | — | 10 | 1.74K | 10.01K | 11.01K | 13.25K | 18.35K | 26.45K | 33.15K | 39.17K | 39.77K | 40.57K | 41.17K | 41.77K | 42.97K | 45.27K | 48.77K | 49.27K | 51.07K |
| Renaissance Technologies | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 23.28K |
| Citadel Advisors | — | — | — | 75.87K | — | — | 25.21K | — | — | 15.44K | 13.63K | — | — | — | — | — | — | — | — | — |
| SmartHarvest Portfolios, LLC | — | — | 13.35K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| XTX Topco Ltd | — | — | — | 10.24K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| BNP PARIBAS FINANCIAL MARKETS | — | — | — | — | — | — | — | — | — | — | 300 | 300 | 300 | — | — | — | — | — | — | — |
| Tower Research Capital LLC (TRC) | — | — | 244 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| CENTRAL TRUST Co | — | — | — | — | — | — | — | — | — | — | — | 200 | — | — | — | — | — | — | — | — |
| GROUP ONE TRADING LLC | — | — | — | — | — | — | — | — | — | — | — | — | 100 | — | — | — | — | — | — | — |
▲ Bought Low (fund opened/added, stock rose ≥5% next quarter) ▼ Sold High (fund reduced, stock fell ≥5% next quarter)
Drag / scroll to zoom · Default shows the most recent year · Annotations come from quarterly fund actions in 13F filings · Hover a marker for details
FAQ
Which funds hold XTLB?
As of 2026-Q2, 3 institutional funds reported holding XTLB (XTL BIOPHARMACEUTICALS LTD) in SEC 13F filings, with a combined reported value of $20.65K.
How many shares of XTLB do institutions own?
13F filers reported 7.57K shares of XTLB, worth $20.65K in aggregate at the end of 2026-Q2.
Is institutional ownership of XTLB rising or falling?
Share counts moved -20.6% versus the prior quarter — distribution.
Who are the top institutional holders of XTLB?
The largest 13F holders are Noked Israel Ltd, Renaissance Technologies, Citadel Advisors, SmartHarvest Portfolios, LLC, RHUMBLINE ADVISERS; the top 25 are ranked at the top of this page.
Who are the major shareholders of XTL BIOPHARMACEUTICALS LTD?
The major shareholders of XTL BIOPHARMACEUTICALS LTD (XTLB) by reported 13F value are Noked Israel Ltd, Renaissance Technologies, Citadel Advisors, SmartHarvest Portfolios, LLC, RHUMBLINE ADVISERS, among 13 institutional holders.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.